Although primary aldosteronism (PA) was formerly seen as a rare cause of hypertension, this condition is now thought to be the commonest cause of secondary hypertension, with the prevalence ranging up to 10-15 % of all hypertensives. Identification of patients with PA allows for specific treatment, for instance unilateral adrenalectomy in case of an aldosterone-producing adenoma or the administration of an aldosterone-receptor antagonist in case of bilateral adrenal hyperplasia.Since the introduction of the aldosterone-renin ratio (ARR) as a screening tool for PA in 1981, there has been considerable debate about the diagnostic value. The values for aldosterone and renin are highly dependent on many factors, including posture, time of day and medication. Also, the cut-off values for the identification of PA remain controversial.This study aims to evaluate the test characteristics of the ARR in a population of patients with therapy-resistant hypertension, the dependence of the ARR on medication type and the predictive value on the response on eplerenone, a selective aldosterone-receptor antagonist.
Study Name: Diagnostic Properties of Aldosterone-Renin Ratio in Primary Aldosteronism Among Hypertensives.
Conditions: Primary aldosteronism Hypertension
Interventions: Drug: eplerenone
Locations: Academical Medical Center, Amsterdam, Netherlands|VU medical Center, Amsterdam, Netherlands|IJsselland Hospital, Capelle aan de IJssel, Netherlands, Beatrix Hospital, Gorinchem, Netherlands|University Medical Center St. Radboud, Nijmegen, Netherlands, Erasmus Medical Center, Rotterdam, Netherlands|, kazia Hospital, Rotterdam, Netherlands, MCRZ, Zuider/Clara, Rotterdam, Netherlands, Oogziekenhuis, Rotterdam, Netherlands, Sint Franciscus Gasthuis, Rotterdam, Netherlands, Vlietland Hospital, Schiedam, Netherlands, Ruwaard van Putten Hospital, Spijkenisse, Netherlands, Twee Steden Ziekenhuis, Waalwijk, Netherlands
Study link: https://ClinicalTrials.gov/show/NCT00407784
To search for other studies by topic, location, or status, go to our Clinical Studies page.